한글목차

단순포진바이러스 치료 시장 규모는 2025년에는 26억 5,360만 달러로 추정되고, 2032년에는 39억 1,170만 달러에 이를 것으로 예측되며, 2025-2032년 CAGR 5.7%로 성장할 것으로 예측됩니다.

단순포진바이러스(HSV)는 생식기 헤르페스와 입술 헤르페스를 일으키는 바이러스 감염입니다. 감염증을 일으키는 매우 전염력이 강한 바이러스입니다. HSV에는 HSV-1과 HSV-2의 2종류가 있습니다. 생식기 헤르페스를 치료할 방법은 없지만 항바이러스제를 매일 사용함으로써 헤르페스 발생을 예방하거나 줄일 수 있습니다. 때문에 안전하고 효과적인 단순포진바이러스 치료에 대한 수요가 전 세계적으로 높아지고 있습니다.

시장 역학 :

단순포진바이러스 감염의 유병률 증가, 임상시험 건수 증가, 안전하고 효과적인 HSV 치료에 대한 수요 증가, 단순포진바이러스에 대한 사람들의 의식 향상은 예측 기간 동안 세계의 단순포진바이러스 치료 시장의 성장을 증가시킬 것으로 예상되는 주요 요인입니다.

예를 들어, 2021년 10월, 유나이티드 바이오파마, 상하이 공중위생 임상센터, 미생물학(성공대학) 및 면역학 부문은 단순포진바이러스 1 및 2(HSV 1과 2)에 의한 생식기 헤르페스에 대한 동급 최고의 장시간 작용 의약품인 UB-621의 효능을 조사하기 위해 제휴했습니다. 게다가 세계 보건 기구(WHO)와 파트너는, HSV 감염의 예방과 제어를 위한 새로운 전략을 개발하기 위한 조사를 지원하고 있습니다.

본 조사의 주요 특징

• 본 보고서는 세계의 단순포진바이러스 치료 시장을 상세하게 분석하여 2024년을 기준 연도로 한 예측 기간(2025-2032년) 시장 규모 및 복합연간 성장률(CAGR)을 제공합니다.
• 또, 다양한 부문에 걸친 잠재적인 수익 기회를 밝혀, 이 시장의 매력적인 투자 제안 매트릭스를 해설했습니다.
• 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 중요한 인사이트도 제공합니다.
• 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등의 다음 파라미터를 바탕으로 세계 단순포진바이러스 치료 시장의 주요 기업 프로파일을 제공합니다.
• 이 보고서의 인사이트를 통해 마케팅 담당자 및 기업의 경영진이, 장래의 제품 발매, 유형 업그레이드, 시장 확대, 마케팅 전술에 관한 정보에 근거한 의사 결정을 실시하는 것을 가능하게 할 것입니다.
• 세계의 단순포진바이러스 치료 시장 보고서는 투자자, 공급자, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 이 업계의 다양한 이해 관계자에 대응하고 있습니다.
• 이해관계자는 세계의 단순포진바이러스 치료 시장 분석에 사용되는 다양한 전략 매트릭스를 통해, 의사 결정을 용이하게 할 수 있습니다.

목차 :

제1장 조사의 목적 및 전제조건

• 조사 목적
• 전제조건
• 약어

제2장 시장 전망

• 보고서 설명
  • 시장 정의 및 범위
• 주요 요약
• 일관된 기회 지도(COM)

제3장 시장 역학, 규제 및 동향 분석

• 시장 역학
  • 단순포진바이러스 감염률 상승
  • 성감염증(STD)에 관한 사회적 편견
  • 안전하고 효과적인 HSV 치료제 수요 증가
• 영향 분석
• 주요 하이라이트
• 규제 시나리오
• 제품 출시 및 승인
• PEST 분석
• Porter's Five Forces 분석
• 합병 및 인수 시나리오

제4장 세계의 단순포진바이러스 치료 시장 : 약제별(2020-2032년)

• 아시클로빌
• 발라시클로빌
• 팜시클로빌
• 기타 약

제5장 세계의 단순포진바이러스 치료 시장 : 투여 경로별(2020-2032년)

• 경구
• 주사
• 외용

제6장 세계의 단순포진바이러스 치료 시장 : 지역별(2020-2032년)

• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제7장 경쟁 구도

• Fresenius SE & Co. KgaA
• Glenmark Pharmaceuticals
• Carlsbad Tech
• GlaxoSmithKline PLC
• Zydus Cadila
• Epi Health LLC
• Viatris Inc.
• Apotex Inc.
• Teva Pharmaceuticals Industries Ltd.
• Emcure Pharmaceuticals Ltd(Avet Pharmaceuticals Inc.)

제8장 섹션

• 조사 방법
• 출판사에 대해

영문목차

Herpes Simplex Virus Treatment Market size is estimated to be valued at USD 2,653.6 Mn in 2025 and is expected to reach USD 3,911.7 Mn in 2032, exhibiting a compound annual growth rate (CAGR) of 5.7% from 2025 to 2032.

The herpes simplex virus (HSV) is a viral infection that causes genital and oral herpes. It is a very contagious virus that causes infections. There are two types of HSV, such as HSV-1 and HSV-2. There is no cure for genital herpes, however, daily use of antiviral medicines can prevent or shorten outbreaks, and reduce the chance of spreading it to others. Thus, there is an increasing demand for safe and effective herpes simplex virus treatment worldwide.

Market Dynamics:

Increase in prevalence of infections of the herpes simplex virus, rise in number of clinical trials, increase in demand for safe and effective HSV treatment, and increase in awareness among people about herpes simplex virus are major factors expected to augment the growth of the global herpes simplex virus treatment market over the forecast period.

For instance, in October 2021, United BioPharma, Shanghai Public Health Clinical Centre, and Department of Microbiology (Cheng Kung University) and Immunology teamed up to investigate the efficacy of UB-621, a best-in-class long-acting medicine for genital herpes caused by simplex viruses 1 and 2 (HSV 1 and 2). Moreover, the World Health Organization (WHO) and partners support research to develop new strategies for prevention and control of HSV infections.

Key features of the study:

• This report provides in-depth analysis of the global herpes simplex virus treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global herpes simplex virus treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Fresenius SE & Co. KgaA, Glenmark Pharmaceuticals, Carlsbad Tech, GlaxoSmithKline PLC, Zydus Cadila, Epi Health LLC, Viatris Inc., Apotex Inc., Teva Pharmaceuticals Industries Ltd., and Emcure Pharmaceuticals Ltd (Avet Pharmaceuticals Inc.), among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global herpes simplex virus treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global herpes simplex virus treatment market.

Detailed Segmentation:

• Global Herpes Simplex Virus Treatment Market, By Drug Type:
  • Acyclovir
  • Valacyclovir
  • Famciclovir
  • Other Drugs
• Global Herpes Simplex Virus Treatment Market, By Route of Administration:
  • Oral
  • Injection
  • Topical
• Global Herpes Simplex Virus Treatment Market, By Geography:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Fresenius SE & Co. KgaA
  • Glenmark Pharmaceuticals
  • Carlsbad Tech
  • GlaxoSmithKline PLC
  • Zydus Cadila
  • Epi Health LLC
  • Viatris Inc.
  • Apotex Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • Emcure Pharmaceuticals Ltd (Avet Pharmaceuticals Inc.)

Table of Contents:

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Geography
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Rise in prevalence of infections of the herpes simplex virus
  • Social stigma about sexually transmitted diseases (STDs)
  • Increase in demand for safe and effective HSV therapeutics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Herpes Simplex Virus Treatment Market, By Drug Type, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Acyclovir
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Valacyclovir
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Famciclovir
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Other Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

5. Global Herpes Simplex Virus Treatment Market, By Route of Administration, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Injection
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Topical
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

6. Global Herpes Simplex Virus Treatment Market, By Geography, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)
• Middle East & Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)

7. Competitive Landscape

• Fresenius SE & Co. KgaA
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Glenmark Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Carlsbad Tech
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline PLC
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Zydus Cadila
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Epi Health LLC
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Viatris Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Apotex Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Teva Pharmaceuticals Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Emcure Pharmaceuticals Ltd (Avet Pharmaceuticals Inc.)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Analyst Views

8. Section

• Research Methodology
• About us